Wall Street Week Ahead

Wall Street faces a holiday-shortened week, with investor attention primarily focused on upcoming labor market data, particularly Friday's August nonfarm payrolls report. Following recent weaker-than-expected job figures and significant downward revisions, further signs of labor market softening could solidify expectations for a Federal Reserve rate cut in September. Additionally, key earnings reports from major tech firms, including Dow 30 component Salesforce and chipmaker Broadcom, are anticipated.

Analysis

The market is facing a pivotal, holiday-shortened week with macroeconomic data poised to be the primary driver of sentiment. All eyes are on Friday's August nonfarm payrolls report, especially after July's figures came in significantly weaker than expected and prior months saw major downward revisions. Any further signs of a deteriorating labor market are likely to solidify investor expectations for a Federal Reserve rate cut in September. On the corporate front, earnings from major technology firms, including Salesforce (CRM) and Broadcom (AVGO), will also be in focus. Deeper-dive analysis highlights two specific dividend-oriented opportunities. AbbVie (ABBV) is presented as a solid long-term dividend growth story, successfully navigating the patent expiry of Humira by focusing on its high-growth assets, Skyrizi and Rinvoq. Despite solid Q2 results and a projected 11% EPS CAGR through 2029, risks such as a high valuation, policy pressure, and debt from the Allergan acquisition warrant caution. Conversely, ONEOK (OKE) is positioned as a compelling buy-the-dip opportunity for income investors following a sharp share price decline. Despite a trimmed 2026 guidance on weaker commodity prices, the company reaffirmed its 2025 EBITDA target, offers a 5.7% dividend yield, maintains low leverage, and trades at a discount to peers, suggesting an attractive risk-reward profile.

Key Decisions for Investors

• Investors should closely monitor the August nonfarm payrolls report, as a weaker-than-expected number would increase the probability of a Fed rate cut, potentially benefiting rate-sensitive equities and fixed income.
• For AbbVie (ABBV), the current high valuation and persistent Humira-related risks suggest a cautious approach, even as its pipeline with Skyrizi and Rinvoq presents a strong long-term growth narrative.
• The recent pullback in ONEOK (OKE) may present a compelling entry point for income-focused investors, given its 5.7% dividend yield and discounted valuation, though exposure to commodity price volatility remains a key risk to monitor.
• Upcoming earnings from Salesforce (CRM) and Broadcom (AVGO) will provide critical insights into enterprise software spending and semiconductor demand, respectively, and could introduce volatility into the technology sector.